European drug regulator rejects Alzheimer’s drug Leqembi, citing safety concerns

The Eu­ro­pean Med­i­cines Agency on Fri­day held its ground against an­ti-amy­loid treat­ments, say­ing it will not rec­om­mend Ei­sai and Bio­gen’s Alzheimer’s drug Leqem­bi for ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.